Neonatal screening for 21 hydroxylase deficiency is designed to detect classical form of congenital adrenal hyperplasia (CAH). It is still unclear whether newborns who result false positives at neonatal screening might later develop signs of androgen excess. The aim of this study is to verify whether a slightly elevated 17-OHP at newborn screening is a predictive factor for premature pubarche.
We evaluated all infants born between 2001 and 2014 with premature pubarche. In case of increased bone age, they were submitted to functional tests to find out the cause of their symptoms. Their 17-OHP values at newborn screening for CAH were reconsidered.
We identified 330 patients (269 females, 61 males) with premature pubarche. All these children had a normal 17-OHP at newborn screening with the exception of a child, born preterm and not affected by CAH.
An elevated 17-OHP at newborn screening is not a predictive factor for premature pubarche. A likely cause of increased 17-OHP level at screening is an immaturity of adrenal gland or a neonatal stress. Therefore a strict follow up of these neonates during childhood is not necessary.
Joint ESPE/LWPES CAH working group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab. 2002;87:4048–53. CrossRef
Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin N Am. 2001;30:15–30. CrossRef
American Academy of Pediatrics, section on Endocrinology and Committee on Genetics. Techical report: congenital adrenal hyperplasia. Pediatrics. 2000;106:1511–8. CrossRef
Grosse SD, Van Vliet G. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res. 2007;67:284–91. PubMed
Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y, Carel JC, DHCSF Study Group. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch Pediatr Adolesc Med. 2012;166:113–20. CrossRefPubMed
Gönç EN, Ozön ZA, Alikaşifoğlu A, Engiz O, Bulum B, Kandemir N. Is basal serum 17-OH progesterone a reliable parameter to predict nonclassical congenital adrenal hyperplasia in premature adrenarche? Turk J Pediatr. 2011;53:274–80. PubMed
ArmengaudJB CML, Trivin C, Tardy V, Bréart G, Brauner R, Chalumeau M. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab. 2009;94:2835–40. CrossRef
Ghizzoni L, Cappa M, Vottero A, Ubertini G, Carta D, Di Iorgi N, Gasco V, Marchesi M, Raggi V, Ibba A, Napoli F, Massimi A, Maghnie M, Loche S, Porzio O. Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche. Eur J Endocrinol. 2011;165:307–14. CrossRefPubMed
Livadas S, Dracopoulou M, Dastamani A, Sertedaki A, Maniati-Christidi M, Magiakou AM, Kanaka-Gantenbein C, Chrousos GP, Dacou-Voutetakis C. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. Clin Endocrinol. 2015;82:543–9. CrossRef
Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford: Stanford University Press; 1959.
New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Panq S, Levine LS. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Met. 1983;57:320–6. CrossRef
Ibáñez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche--normal variant or forerunner of adult disease? Endocr Rev. 2000;21:671–96. PubMed
Leite MV, Mendonça BB, Arnhold IJ, Estefan V, Nunes C, Nicolau W, Bloise W. Identification of nonclassical 21-hydroxylase deficiency in girls with precocious pubarche. J Endocrinol Investig. 1991;14:11–5. CrossRef
Knorr D, Bidlingmaier F, Höller W, Kuhnle U, Meiler B, Nachmann A. Is heterozygosity for the steroid 21-hydroxylase deficiency responsible for hirsutism, premature pubarche, early puberty, and precocious puberty in children? Acta Endocrinol Suppl (Copenh). 1986;279:284–9.
Skordis N, Shammas C, Phedonos AA, Kyriakou A, Toumba M, Neocleous V, Phylactou LA. Genetic defects of the CYP21A2 gene in girls with premature adrenarche. J Endocrinol Investig. 2015;38:535–9. CrossRef
Neocleous V, Shammas C, Phedonos AP, Karaoli E, Kyriakou A, Toumba M, Phylactou LA, Skordis N. Genetic defects in the cyp21a2 gene in heterozygous girls with premature adrenarche and adolescent females with hyperandrogenemia. Georgian Med News. 2012;210:40–7.
Knochenhauer ES, Cortet-Rudelli C, Cunnigham RD, Conway-Myers BA, Dewailly D, Azziz R. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. J Clin Endocrinol Metab. 1997;82:479–85. PubMed
Admoni O, Israel S, Lavi I, Gur M, Tenenbaum-Rakover Y. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype. Clin Endocrinol. 2006;64:645–51. CrossRef
Working Group on Neonatal Screening of the European Society for Paediatric Endocrinology. Procedure for neonatal screening for congenital adrenal hyperplasia due to 21-hydroxilase deficiency. Horm Res. 2001;55:201–5.
White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21:245–91. PubMed
Torresani T, Grüters A, Acherz R. Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17-α-hydroxyprogesterone to gestational age. Screening. 1994;3:77–84. CrossRef
Honour JW, Torresani T. Evaluation of neonatal screening for congenital adrenal hyperplasia. Horm Res. 2001;55:206–11. PubMed
Van Der Kamp HJ, Oudshoorn CGM, Elvers BH, Van Baarle M, Otten BJ, Wit JM, Verkerk PH. Cut-off level of 17-α-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab. 2005;90:3904–7. CrossRefPubMed
Gruñeiro-Papendieck L, Prieto L, Chiesa A, Bengolea S, Bossi G, Bergadá C. Neonatal screening program for congenital adrenal hyperplasia: adjustments to the recall protocol. Horm Res. 2001;55:271–7. PubMed
Hayashi GY, Carvalho DF, de Miranda MC, Faure C, Vallejos C, Brito VN, Rodrigues AS, Madureira G, Mendonca BB, Bachega TA. Neonatal 17-hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening. Clin Endocrinol. 2017;86:480–7. CrossRef
Cavarzere P, Camilot M, Teofoli F, Tatò L. Neonatal screening for congenital adreanl hyperplasia in North-eastern Italy: a report three years into the program. Horm Res. 2005;63:180–6. PubMed
Hingre RV, Gross SJ, Hingre KS, Mayes DM, Richman RA. Adrenal steroidogenesis in very low birth weight preterm infants. J Clin Endocrinol Metab. 1994;78:266–70. PubMed
Root AW. Editorial: neonatal screening for 21-hydroxylase deficient congenital adrenal hyperplasia-the role of CYP21 analysis. J Clin Endocrinol Metab. 1999;84:1503–4. PubMed
- Children with premature pubarche: is an alterated neonatal 17-Ohp screening test a predictive factor?
Diego Alberto Ramaroli
- BioMed Central